The current study was designed to evaluate the potential of valproic acid (VPA) as a prototype HDAC inhibitor of growth and proliferation in temsirolimus-resistant prostate cancer cells by exploring its underlying molecular mode of action. This evidence concerns the gene HDAC9 and prostate carcinoma.